Literature DB >> 35364709

Reproducibility of volume analysis of dynamic susceptibility contrast perfusion-weighted imaging in untreated glioblastomas.

Margaux Roques1,2, Magali Raveneau3, Gilles Adam3, Amaury De Barros4, Isabelle Catalaa3, Sofia Patsoura3, Christophe Cognard3, Jean Darcourt3, Fabrice Bonneville3,5.   

Abstract

PURPOSE: Despite a high variability, the hotspot method is widely used to calculate the cerebral blood volume (CBV) of glioblastomas on DSC-MRI. Our aim was to investigate inter- and intra-observer reproducibility of parameters calculated with the hotspot or a volume method and that of an original parameter assessing the fraction of pixels in the tumour volume displaying rCBV > 2: %rCBV > 2.
METHODS: Twenty-seven consecutive patients with untreated glioblastoma (age: 63, women: 11) were retrospectively included. Three observers calculated the maximum tumour CBV value (rCBVmax) normalized with a reference ROI in the contralateral white matter (CBVWM) with (i) the hotspot method and (ii) with a volume method following tumour segmentation on 3D contrast-enhanced T1-WI. From this volume method, %rCBV > 2 was also assessed. After 8-12 weeks, one observer repeated all delineations. Intraclass (ICC) and Lin's (LCC) correlation coefficients were used to determine reproducibility.
RESULTS: Inter-observer reproducibility of rCBVmax was fair with the hotspot and good with the volume method (ICC = 0.46 vs 0.65, p > 0.05). For CBVWM, it was fair with the hotspot and excellent with the volume method (0.53 vs 0.84, p < 0.05). Reproducibility of one pairwise combination of observers was significantly better for both rCBVmax and CBVWM (LCC = 0.33 vs 0.75; 0.52 vs 0.89, p < 0.05). %rCBV > 2 showed excellent inter- and intra-observer reproducibility (ICC = 0.94 and 0.91).
CONCLUSION: Calculated in glioblastomas with a volume method, rCBVmax and CBVWM yielded good to excellent reproducibility but only fair with the hotspot method. Overall, the volume analysis offers a highly reproducible parameter, %rCBV > 2, that could be promising during the follow-up of such heterogeneous tumours.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cerebral blood volume; Dynamic susceptibility contrast; Glioblastoma; Neuro-oncology; Observer variation

Mesh:

Substances:

Year:  2022        PMID: 35364709     DOI: 10.1007/s00234-022-02937-6

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.995


  5 in total

1.  Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity.

Authors:  Janine M Lupo; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

2.  Perfusion MRI-Based Fractional Tumor Burden Differentiates between Tumor and Treatment Effect in Recurrent Glioblastomas and Informs Clinical Decision-Making.

Authors:  M Iv; X Liu; J Lavezo; A J Gentles; R Ghanem; S Lummus; D E Born; S G Soltys; S Nagpal; R Thomas; L Recht; N Fischbein
Journal:  AJNR Am J Neuroradiol       Date:  2019-09-12       Impact factor: 3.825

3.  Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not.

Authors:  J L Boxerman; K M Schmainda; R M Weisskoff
Journal:  AJNR Am J Neuroradiol       Date:  2006-04       Impact factor: 3.825

4.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging.

Authors:  Meng Law; Stanley Yang; Hao Wang; James S Babb; Glyn Johnson; Soonmee Cha; Edmond A Knopp; David Zagzag
Journal:  AJNR Am J Neuroradiol       Date:  2003 Nov-Dec       Impact factor: 3.825

5.  Pseudoprogression of brain tumors.

Authors:  Stefanie C Thust; Martin J van den Bent; Marion Smits
Journal:  J Magn Reson Imaging       Date:  2018-05-07       Impact factor: 4.813

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.